- Trials with a EudraCT protocol (8)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
8 result(s) found for: Corpus Callosum.
Displaying page 1 of 1.
EudraCT Number: 2014-002710-23 | Sponsor Protocol Number: P140203 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP) | |||||||||||||
Full Title: | |||||||||||||
Medical condition: | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-003762-41 | Sponsor Protocol Number: DTI-001 | Start Date*: 2006-08-17 |
Sponsor Name:Department of Psychiatry, Ludwig-Maximilian University Munich | ||
Full Title: Diffusionstensorgewichtete MRT bei der Alzheimer Krankheit: Prädiktion und Darstellung von symptomatischen und krankheitsmodifizierenden Behandlungseffekten von Galantamin (Reminyl®) | ||
Medical condition: Alzheimer's disease | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2019-001542-17 | Sponsor Protocol Number: T109/2019Xe-SAH | Start Date*: 2020-09-17 | |||||||||||
Sponsor Name:Timo Laitio | |||||||||||||
Full Title: Effect of xenon on brain injury, neurological outcome and survival in patients after aneurysmal subarachnoid hemorrhage | |||||||||||||
Medical condition: Acute rupture of cerebral aneurysm, subarachnoid hemorrhage (SAH), unconsciousness, brain injury. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-000721-31 | Sponsor Protocol Number: RIDOSE-MS | Start Date*: 2018-07-04 |
Sponsor Name:Department of Clinical Sciences, Karolinska Institutet Danderyd Hospital | ||
Full Title: RItuximab Long-Term DOSE Trial in Multiple Sclerosis – RIDOSE-MS A randomized trial of long-term dosage of rituximab in multiple sclerosis The RIDOSE-MS trial is a multi-centre trial of long-term ... | ||
Medical condition: Patients with multiple sclerosis (MS), 20 - 52 years of age, that have completed the RIFUND-MS trial (EudraCT 2015-004116-38) will be offered to continue in this extension trial, RODOSE-MS. In addi... | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: SE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2020-002924-35 | Sponsor Protocol Number: APHP180592 | Start Date*: 2021-01-18 |
Sponsor Name:ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS | ||
Full Title: Prenatal treatment of congenital cytomegalovirus infection with letermovir randomized against valaciclovir | ||
Medical condition: Step 1: Maternal administration of 1 tablet of Letermovir (240 mg or 480 mg /day) during 3 days before TOP Step 2: Maternal daily administration of 240 or 480 milligrams of letermovir (1x240 mg-ta... | ||
Disease: | ||
Population Age: Children, Under 18, Adults | Gender: Female | |
Trial protocol: FR (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2020-004802-70 | Sponsor Protocol Number: APHP200491 | Start Date*: 2021-08-03 |
Sponsor Name:Assistance Publique – Hôpitaux de Paris | ||
Full Title: Impact of post-ARDS COVID sedation on late neuroinflammation | ||
Medical condition: All patients who have developed and survived ARDS linked to COVID-19 infection, admitted to intensive care units, meeting the study's inclusion criteria may be included in this research. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2019-002827-14 | Sponsor Protocol Number: TreatSPG11 | Start Date*: 2021-01-19 | |||||||||||
Sponsor Name:IRCCS Fondazione Stella Maris | |||||||||||||
Full Title: Phase 2 pharmacological experimental study to test the safety of miglustat in subjects with hereditary spastic paraplegia type 11 | |||||||||||||
Medical condition: Spastic paraparesis type 11 (SPG11), caused by mutations in spatacsin protein, is characterized by the association of peripheral neuropathy, parkinsonism, ataxia, cognitive impairment, hypotrophy o... | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-003556-31 | Sponsor Protocol Number: SHP-607-201 | Start Date*: 2015-02-10 |
Sponsor Name:Premacure AB, A Member of the Shire Group of Companies | ||
Full Title: Long-term Outcome of Children Enrolled in Study ROPP-2008-01 Previously Treated with rhIGF-1/rhIGFBP-3 for the Prevention of Retinopathy of Prematurity (ROP) or Who Received Standard Neonatal Care | ||
Medical condition: Retinopathy of Prematurity (ROP) | ||
Disease: | ||
Population Age: Newborns, Under 18 | Gender: Male, Female | |
Trial protocol: SE (Completed) GB (GB - no longer in EU/EEA) NL (Completed) PL (Completed) IT (Completed) | ||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.